Evidence map›Paper›PMID 38084670›Full record

ArticlePediatric obesity2024

Endotoxin biomarkers, hepatic fat fraction, liver volume and liver stiffness among adolescents at high-risk for non-alcoholic fatty liver disease: The HEROES study.

Wei Perng, Kyle Salmon, Rachel Schenker, Rachel C Janssen, Jacob E Friedman, Michael I Goran

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric obesity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wei PerngDepartment of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0001-8552-6850
Kyle SalmonDepartment of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rachel SchenkerDepartment of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA.
Rachel C JanssenHarold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Jacob E FriedmanHarold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Michael I GoranDepartment of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA.
Children's Hospital of Los Angeles · USColorado School of Public Health · USUniversity of Oklahoma Health Sciences Center · US

Funding

Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChilLDRen) Clinical Centers.U01DK084538 · NIDDK · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KOHLI, ROHIT · 2009 to 2023
$4.8M
Institutional Career Development CoreKL2TR002534 · NCATS · UNIVERSITY OF COLORADO DENVER · PI BURNHAM, ELLEN L · 2018 to 2022
$4.6M
Nutrigenetic Intervention to Reduce Liver Fat in Hispanics - SupplementR01MD010358 · NIMHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALLAYEE, HOOMAN, GORAN, MICHAEL ISAAC · 2016 to 2019
$3.3M
CTSA K12 Program at University of Colorado DenverK12TR004412 · NCATS · UNIVERSITY OF COLORADO DENVER · PI ELLEN L BURNHAM · 2024 to 2026
$3.2M
Understanding the Pathophysiology of Type 2 Diabetes in Navajo YouthU01DK134981 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Dana Dabelea, Wei Perng · 2023 to 2026
$2.7M
Understanding the metabolic pathology of pediatric obesity and NAFLDR01DK129656 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI FRIEDMAN, JACOB E, SHORT, KEVIN R. · 2022 to 2025
$2.2M
Translational Research Training in HepatologyT32DK127977 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Rohit Kohli, Norah A. Terrault · 2022 to 2026
$1.3M
NCATS NIH HHS K12 TR004412NCATS NIH HHS KL2 TR002534NIDDK NIH HHS R01 DK129656NIDDK NIH HHS T32 DK127977NIDDK NIH HHS U01 DK084538NIDDK NIH HHS U01 DK134981NIH HHS R01DK129656NIH HHS R01MD010358NIH HHS U01DK134981NIMHD NIH HHS R01 MD010358
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is on the rise among youth. Identifying biomarkers of NAFLD progression/risk can aid in prevention efforts.

aimsThis pilot study investigated associations of two endotoxin biomarkers-lipopolysaccharide-binding protein (LBP) and anti-endotoxin core immunoglobulin G (EndoCab)-with markers of NAFLD among 99 Latino/Latina adolescents (11-19 years) with obesity. MATERIALS &

methodsWe used linear regression to examine associations of each endotoxin biomarker (per 1-SD) with hepatic fat fraction (HFF), liver volume, and liver stiffness.

resultsWe found positive associations of LBP with HFF and liver volume. Each 1-SD increment in LBP corresponded with 2.35% (95% CI: 0.46%, 4.23%) higher HFF and 0.14 (0.06, 0.23) L greater liver volume after adjusting for age, sex, and maternal education. Accounting for abdominal adiposity and Tanner stage did not change results. Excluding 72 participants with NAFLD attenuated associations of LBP with HFF but associations with liver volume persisted (0.11 [0.01, 0.21] L). EndoCab was not associated with any liver outcomes. Neither endotoxin biomarker predicted liver stiffness. DISCUSSION/

conclusionWhile additional research is warranted, our results support LBP as a biomarker of NAFLD risk/progression in high-risk youth.

Indexed as

Non-alcoholic Fatty Liver DiseaseAdolescentBiomarkersEndotoxinsHumansLiverPilot ProjectsBiomarkersEndotoxinsadiposityendotoxinhepatic fat fractionliver elasticitynon-alcoholic fatty liver diseasevisceral fat

Identifiers

PMID38084670
PMCPMC10872969
OpenAlexW4389607084

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.